(Stockholm, a clinical-stage biotech company treating lifestyle diseases such as diabetes and obesity): Has raised 44 MSEK in a funding round from existing investors together with new investors Martin Bjäringer and Ulf Wiinberg. Early investors in Sigrid include founding member Lars Lindgren. “We are ‘deep tech’ and have needed to research, develop, patent, and scale up production in a highly regulated industry. This will be the first time we start making money. It feels incredibly huge for me and the team,” comments Sana Alajmovic.